

Review Paper

Molecular and Cellular Mechanisms of Intervertebral Disc Degeneration: A Narrative Mini-review



Khatere Mokhtari^{1*}

1. Department of Cell and Molecular Biology and Microbiology, Faculty of Biological Science and Technology, University of Isfahan, Isfahan, Iran.



Citation Mokhtari Kh. Molecular and Cellular Mechanisms of Intervertebral Disc Degeneration: A Narrative Mini-review. *Journal of Research in Orthopedic Science*. 2026; 13(1):1-4. <http://dx.doi.org/10.32598/JROSJ.13.1.2718.3>

<http://dx.doi.org/10.32598/JROSJ.13.1.2718.3>

Article info:

Received: 10 Jul 2025

Revised: 15 Dec 2025

Accepted: 27 Dec 2025

Keywords:

Disc degeneration, Low back pain, Inflammatory signaling, Extracellular matrix (ECM) degradation

ABSTRACT

Intervertebral disc degeneration (IVDD) is a major contributor to low back pain and spinal disorders, representing a significant global health burden. Once considered a consequence of aging and mechanical stress, IVDD is now recognized as a multifactorial process involving complex molecular and cellular mechanisms. This narrative mini-review summarizes current insights into the pathophysiology of IVDD, focusing on inflammatory signaling, extracellular matrix (ECM) degradation, oxidative stress, mitochondrial dysfunction, and cellular senescence. Understanding these interconnected pathways provides a foundation for developing targeted and regenerative therapeutic strategies.

* Corresponding Author:

Khatere Mokhtari, PhD.

Address: Department of Cell and Molecular Biology and Microbiology, Faculty of Biological Science and Technology, University of Isfahan, Isfahan, Iran.

Phone: +98 (902) 1381373

E-mail: khatere_mokhtari@yahoo.com



Copyright © 2026 The Author(s);
This is an open access article distributed under the terms of the Creative Commons Attribution License (CC-BY-NC 4.0: <https://creativecommons.org/licenses/by-nc/4.0/legalcode.en>), which permits use, distribution, and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

Introduction

Intervertebral disc degeneration (IVDD) is a leading cause of low back pain and disability worldwide, affecting millions of individuals and imposing a substantial socioeconomic burden. The intervertebral disc is a complex structure composed of the nucleus pulposus (NP), annulus fibrosus, and cartilage endplates, which together maintain spinal flexibility and load distribution. Under physiological conditions, disc homeostasis is maintained by balancing between extracellular matrix (ECM) synthesis and degradation. However, accumulating evidence indicates that IVDD is not merely a passive degenerative process but an active, cell-mediated disease involving inflammation, metabolic alterations, and biomechanical stress [1, 2].

A key feature of IVDD is the disruption of ECM integrity, particularly within the NP, where proteoglycans, such as aggrecan and type II collagen, are essential for maintaining hydration and mechanical resilience. During degeneration, there is a shift toward catabolic activity driven by increased expression of matrix-degrading enzymes, including matrix metalloproteinases and aggrecanases, such as a disintegrin and metalloproteinase with thrombospondin motifs4 (ADAMTS-4) and a disintegrin and metalloproteinase with thrombospondin motifs5 (ADAMTS-5) [3, 4]. This enzymatic degradation results in loss of disc height, reduced hydration, and compromised biomechanical function. The imbalance between anabolic and catabolic processes is largely mediated by pro-inflammatory cytokines, particularly interleukin-1 β (IL-1 β) and tumor necrosis factor- α , which are upregulated in degenerated discs [5, 6].

These cytokines activate key intracellular signaling pathways, including nuclear factor- κ B (NF- κ B) and mitogen-activated protein kinases (MAPKs), leading to increased transcription of inflammatory mediators and catabolic enzymes [7]. This inflammatory microenvironment not only accelerates ECM breakdown but also inhibits matrix synthesis by disc cells. Furthermore, inflammation has been implicated in nociceptive signaling, linking molecular degeneration to clinical symptoms such as chronic low back pain [8-10].

Oxidative stress is another critical contributor to IVDD. Excessive production of reactive oxygen species (ROS) in disc cells leads to oxidative damage of DNA, proteins, and lipids, ultimately impairing cellular function [11]. Mitochondrial dysfunction further exacerbates ROS accumulation and disrupts energy metabolism, creating a detrimental feedback loop that accelerates degeneration.

Studies have shown that oxidative stress also enhances inflammatory signaling pathways, reinforcing the interplay between these mechanisms [12, 13].

Cellular senescence and apoptosis are central to the progressive loss of functional disc cells. Senescent cells accumulate in degenerated discs and exhibit a senescence-associated secretory phenotype, characterized by the release of pro-inflammatory cytokines and matrix-degrading enzymes [14]. This phenotype contributes to chronic inflammation and perpetuates tissue degradation. In parallel, increased apoptosis of NP cells reduces the disc's regenerative capacity, further compromising its structural integrity [15, 16].

Recent advances in basic science have highlighted the role of epigenetic regulation, including microRNAs and long non-coding RNAs, in modulating gene expression during IVDD [17]. These regulatory molecules influence key pathways involved in inflammation, apoptosis, and ECM metabolism. In addition, extracellular vesicles, particularly exosomes, have emerged as important mediators of intercellular communication within the disc microenvironment and represent promising therapeutic tools for regenerative medicine [18, 19].

Mechanical loading and altered biomechanics also play a significant role in IVDD. Abnormal mechanical stress can disrupt disc cell metabolism and activate mechanotransduction pathways that promote catabolic responses [2]. The interplay between mechanical and molecular factors underscores the complexity of IVDD. It supports the concept of the spine as a dynamic system in which structural and biological changes are closely linked.

Taken together, IVDD is driven by a network of inter-related mechanisms involving inflammation, oxidative stress, cellular dysfunction, and biomechanical alterations. This integrated understanding has shifted the focus of research toward identifying disease-modifying therapies that target underlying molecular pathways rather than solely addressing symptoms.

Conclusion

IVDD is a multifactorial and biologically active process involving complex interactions among inflammatory, oxidative, and mechanical factors. Advances in basic science have provided critical insights into the molecular mechanisms driving disc degeneration and have identified potential targets for regenerative and disease-modifying therapies. Bridging these findings with clinical applications remains essential for improving patient outcomes in spinal disorders.

Ethical Considerations

Compliance with ethical guidelines

There were no ethical considerations to be considered in this research.

Funding

This research did not receive any grant from funding agencies in the public, commercial, or non-profit sectors.

Conflict of interest

The author declared no conflict of interest.

References

- [1] Adams MA, Roughley PJ. What is intervertebral disc degeneration, and what causes it? *Spine*. 2006; 31(18):2151-61. [DOI:10.1097/01.brs.0000231761.73859.2c] [PMID]
- [2] Adams MA, Roughley PJ. Degeneration of the intervertebral disc. *Arthritis Res Ther*. 2003; 5(3):120-30. [DOI:10.1186/ar629] [PMID]
- [3] Le Maitre CL, Freemont AJ, Hoyland JA. The role of interleukin-1 in the pathogenesis of human intervertebral disc degeneration. *Arthritis Res Ther*. 2005; 7(4):R732-45. [DOI:10.1186/ar1732] [PMID]
- [4] Le Maitre CL, Hoyland JA, Freemont AJ. Interleukin-1 receptor antagonist delivered directly and by gene therapy inhibits matrix degradation in the intact degenerate human intervertebral disc: An in situ zymographic and gene therapy study. *Arthritis Res Ther*. 2007; 9(4):R83. [DOI:10.1186/ar2282] [PMID]
- [5] Risbud MV, Shapiro IM. Role of cytokines in intervertebral disc degeneration: Pain and disc content. *Nat Rev Rheumatol*. 2014; 10(1):44-56. [DOI:10.1038/nrrheum.2013.160] [PMID]
- [6] Johnson ZI, Schoepflin ZR, Choi H, Shapiro IM, Risbud MV. Disc in flames: Roles of TNF- α and IL-1 β in intervertebral disc degeneration. *Eur Cell Mater*. 2015; 30:104-16; discussion 116-7. [DOI:10.22203/eCM.v030a08] [PMID]
- [7] Vo NV, Hartman RA, Yurube T, Jacobs LJ, Sowa GA, Kang JD. Expression and regulation of metalloproteinases and their inhibitors in intervertebral disc aging and degeneration. *Spine J*. 2013; 13(3):331-41. [DOI:10.1016/j.spinee.2012.02.027] [PMID]
- [8] Freemont AJ. The cellular pathobiology of the degenerate intervertebral disc and discogenic back pain. *Rheumatology (Oxford)*. 2009; 48(1):5-10. [DOI:10.1093/rheumatology/ken396] [PMID]
- [9] Hughes SP, Freemont AJ, Hukins DW, McGregor AH, Roberts S. The pathogenesis of degeneration of the intervertebral disc and emerging therapies in the management of back pain. *J Bone Joint Surg Br*. 2012; 94(10):1298-304. [DOI:10.1302/0301-620X.94B10.28986] [PMID]
- [10] Richardson SM, Freemont AJ, Hoyland JA. Pathogenesis of intervertebral disc degeneration. In: Shapiro I, Risbud M, editors. *The intervertebral disc*. Vienna: Springer; 2014. [DOI:10.1007/978-3-7091-1535-0_11]
- [11] Feng C, Yang M, Lan M, Liu C, Zhang Y, Huang B, et al. ROS: Crucial intermediators in the pathogenesis of intervertebral disc degeneration. *Oxid Med Cell Longev*. 2017; 2017:5601593. [DOI:10.1155/2017/5601593] [PMID]
- [12] Song C, Xu Y, Peng Q, Chen R, Zhou D, Cheng K, et al. Mitochondrial dysfunction: A new molecular mechanism of intervertebral disc degeneration. *Inflamm Res*. 2023; 72(12):2249-60. [DOI:10.1007/s00011-023-01813-0] [PMID]
- [13] Wang DK, Zheng HL, Zhou WS, Duan ZW, Jiang SD, Li B, et al. Mitochondrial dysfunction in oxidative stress-mediated intervertebral disc degeneration. *Orthop Surg*. 2022; 14(8):1569-82. [DOI:10.1111/os.13302] [PMID]
- [14] Feng C, Liu H, Yang M, Zhang Y, Huang B, Zhou Y. Disc cell senescence in intervertebral disc degeneration: Causes and molecular pathways. *Cell Cycle*. 2016; 15(13):1674-84. [DOI:10.1080/15384101.2016.1152433] [PMID]
- [15] Zhao CQ, Zhang YH, Jiang SD, Jiang LS, Dai LY. Both endoplasmic reticulum and mitochondria are involved in disc cell apoptosis and intervertebral disc degeneration in rats. *Age (Dordr)*. 2010; 32(2):161-77. [DOI:10.1007/s11357-009-9121-4] [PMID]
- [16] Zhao CQ, Jiang LS, Dai LY. Programmed cell death in intervertebral disc degeneration. *Apoptosis*. 2006; 11(12):2079-88. [DOI:10.1007/s10495-006-0290-7] [PMID]
- [17] Jiang J, Sun Y, Xu G, Wang H, Wang L. The role of miRNA, lncRNA and circRNA in the development of intervertebral disk degeneration (Review). *Exp Ther Med*. 2021; 21(6):555. [DOI:10.3892/etm.2021.9987] [PMID]
- [18] Wang HS, Lin S, Yu HM. Exosome-mediated repair of intervertebral disc degeneration: The potential role of miRNAs. *Curr Stem Cell Res Ther*. 2024; 19(6):798-808. [DOI:10.2174/1574888X18666230504094233] [PMID]
- [19] Xia C, Zeng Z, Fang B, Tao M, Gu C, Zheng L, et al. Mesenchymal stem cell-derived exosomes ameliorate intervertebral disc degeneration via anti-oxidant and anti-inflammatory effects. *Free Radic Biol Med*. 2019; 143:1-15 [DOI:10.1016/j.freeradbiomed.2019.07.026] [PMID]

This Page Intentionally Left Blank